Neumora Therapeutics (NMRA) grants 750,000 options with vesting detail

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. reported a Form 4 transaction for officer Daljit Singh Aurora, its Chief Operating and Development Officer. On January 8, 2026, Aurora received a stock option to buy 750,000 shares of common stock at an exercise price of $2.33 per share, with no cost reported for the option itself.

All 750,000 derivative securities are shown as beneficially owned directly after the grant. The option vests over four years: 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the option is fully vested and exercisable on the fourth anniversary of that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Aurora Daljit Singh

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	750,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 750,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aurora Daljit Singh

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL WAY, SUITE 1

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.33	01/08/2026		A		750,000		(1)	01/08/2036	Common Stock	750,000	$0	750,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: Chief Operating and Development Officer

	/s/ Michael Milligan, as Attorney-in-Fact for Daljit Singh Aurora	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in the Neumora Therapeutics (NMRA) Form 4 filing?

The reporting person is Aurora Daljit Singh, who serves as Chief Operating and Development Officer of Neumora Therapeutics, Inc.

What securities were granted in this Neumora Therapeutics (NMRA) Form 4?

The filing reports a grant of a Stock Option (Right to Buy) covering 750,000 shares of common stock with an exercise price of $2.33 per share.

When did the reported stock option grant for NMRA occur?

The stock option grant to Aurora Daljit Singh has a transaction date of January 8, 2026, as shown in the derivative securities table.

How many derivative securities does the Neumora executive own after this Form 4 transaction?

Following the reported transaction, the Form 4 shows 750,000 derivative securities beneficially owned, corresponding to the granted stock option.

What is the vesting schedule for the 750,000 Neumora (NMRA) stock options?

According to the footnote, 25% of the option shares vest on the first anniversary of January 8, 2026, and 1/48th of the total shares vest monthly thereafter so that the option is fully vested and exercisable on the fourth anniversary.

Is the Neumora Therapeutics stock option held directly or indirectly by the reporting person?

The Form 4 lists direct (D) ownership for the 750,000 derivative securities held by the reporting person.